Devyser Diagnostics AB publishes quarterly report for July to September 2023
“Devyser is reporting record sales growth (+50% organic growth) for the third quarter, a further improvement in EBIT and continued high gross margins. Devyser’s transplant products were given IVDR approvals during the quarter and Thermo Fisher Scientific, our commercial partner in the transplant field, began the launching of the transplant products in North America and Europe.” Fredrik Alpsten, CEO, Devyser The quarter from July to September 2023 · Net sales amounted to SEK 46.7 million (31.2), corresponding to a 49.8 percent increase. Adjusted for exchange rate fluctuations, net